Single MIJ821 injection added to treatment-resistant depression care
About this title
Read the official source — NCT05454410Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 15 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 60
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Japan, Poland, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05454410
- Official title
Show the full official title
A Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Single Subcutaneous MIJ821 Injection in Addition to Standard of Care in Participants With Treatment-resistant Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Birmingham, United States · Oakland Park, United States · Tampa, United States
11 more locations
- Yokohama, Japan
- Kodaira, Japan
- Mitaka, Japan
- Bialystok, Poland
- Gdansk, Poland
- Swiecie North West, Poland
- Seville, Spain
- Sabadell, Spain
- Sant Boi de Llobregat, Spain
- Barcelona, Spain
- Pamplona, Spain
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Novartis Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg and Placebo Subcutaneous Injection.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
